CPSE:NOVO BPharmaceuticals
Novo Nordisk Reworks Odense Plant As Wegovy Data Shapes Growth Story
Novo Nordisk (CPSE:NOVO B) has cancelled a planned rare disease manufacturing facility in Odense valued at about $1.33b and will instead convert the site into a warehouse.
The decision marks a shift in how the company is allocating capital and production capacity across its portfolio of treatments, including obesity and rare diseases.
At the European Congress on Obesity, new late stage data from the OASIS 4, STEP UP, and SELECT trials highlighted the efficacy of oral and high dose Wegovy for...